Genesis to launch Phase II eczema trial in UK
10 September, 2003 by Graeme O'NeillAuckland biopharma Genesis Research and Development Corporation (NSX/ASX:GEN) is to begin a Phase II clinical trial of its AVAC therapy for paediatric atopic dermatitis, or childhood eczema.
GTG promises more licensing revenue in coming year
10 September, 2003 by Melissa TrudingerMelbourne biotech Genetic Technologies (ASX:GTG) has released its financial results for 2002-03 financial year, showing a 29 per cent revenue drop to AUD$9.26 million and a net loss of $4.16 million, an improvement over last year's $8.8 million loss.
Starpharma raises $6.9m
10 September, 2003 by Melissa TrudingerPooled investment firm and nanotech specialist Starpharma (ASX:SPL) has raised AUD$6.9 million in an oversubscribed placement to institutional and sophisticated investors.
Prana touts development as possible Alzheimer's therapy
10 September, 2003 by Graeme O'NeillMelbourne-based biomedical company Prana Biotechnology (ASX:PBT) has announced it has developed a set of assays for high-throughput testing of molecules with therapeutic potential for Alzheimer's disease.
Peplin blames R&D expenditure for loss
09 September, 2003 by Graeme O'NeillBrisbane cancer-drug developer Peplin Biotech (ASX:PEP) has reported a consolidated loss of AUD$3.7 million for the 12 months to June 30, largely attributable to a big increase in research expenditure on its lead compound, PEP005.
GTG acquires sports gene test rights from Sydney Uni
08 September, 2003 by Melissa TrudingerMelbourne genetic testing company Genetic Technologies (ASX:GTG) has acquired the exclusive worldwide rights to commercialise a test for a gene underlying athletics and sports performance from the University of Sydney.
EpiTan loss doesn't detract from solid year
08 September, 2003 by Melissa TrudingerMelbourne biotech company EpiTan (ASX:EPT) has posted a loss of AUD$4 million for the 2002-2003 financial year, primarily due to the expenses of running Phase II clinical trials on its lead drug candidate Melanotan.
Prana raises $5m from institutional investors
08 September, 2003 by Melissa TrudingerJoining the list of companies taking advantage of increased investor interest in the biotechnology sector, Prana Biotechnology (ASX:PBT) has raised AUD$5 million in a placement to institutional and sophisticated investors at a price of $0.70 per share.
Xcell collaborators earn $1m NIH grant
05 September, 2003 by Melissa TrudingerCollaborators of Perth devices company Xcell Diagnostics (ASX:XEL) have received a US NIH grant worth more than AUD$1 million (US$702,000) to perform clinical studies on Xcell's Funhaler paediatric asthma spacer device.
Biotron adds dengue virus to discovery roster
04 September, 2003 by Graeme O'NeillCanberra biotechnology company Biotron (ASX: BIT) has added dengue virus to the lengthening list of potentially lethal human viruses that possess ion-channel genes.
UK hints at end to drug price controls
03 September, 2003 by Richard WoodmanThe British government said it might be possible to relax or abolish price and profit controls on branded prescription medicines in the UK.
Agenix appoints new US vet distributor
03 September, 2003 by Iain ScottBrisbane-based Agenix (ASX:AGX) has appointed a new distributor for its animal health diagnostic products in the US.
Anadis therapy aiming to ease travellers' paths
03 September, 2003 by Graeme O'NeillIt's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip.
Patent could lead to new royalty revenue: CSL
03 September, 2003 by Iain ScottA new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US.
PanBio tips profit for 2003-04
02 September, 2003 by Melissa TrudingerQueensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today.
